First-Line Versus Second-Line Use of Reslizumab in Severe Uncontrolled Asthma
J. investig. allergol. clin. immunol
; 33(3): 220-222, 2023. tab
Article
in English
| IBECS
| ID: ibc-221945
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
Full text:
Available
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Asthma
/
Anti-Asthmatic Agents
/
Antibodies, Monoclonal, Humanized
Limits:
Humans
Language:
English
Journal:
J. investig. allergol. clin. immunol
Year:
2023
Document type:
Article
Institution/Affiliation country:
Complejo Asistencial de Ávila/Spain
/
Galdakao Hospital/Spain
/
Hospital Costa del Sol/Spain
/
Hospital Lucus Augusti/Spain
/
Hospital Universitario 12 de Octubre/Spain
/
Hospital Universitario Donostia/Spain
/
Hospital Universitario Fundación Alcorcón/Spain
/
Hospital Universitario Son Espases/Spain
/
Hospital Universitario de Cruces/Spain
/
University Hospital of Jerez/Spain